A transgenic mouse model of human systemic Apoa2 amyloidosis

Merrill Benson, A. D. Kalopissis, M. Charbert, J. J. Liepnieks, B. Kluve-Beckerman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Apolipoprotein AII (apoAII) amyloidosis an autosomal dominant inherited form of amyloidosis caused by mutations in the stop codon for the apoAII gene is characterized by progressive renal and cardiac amyloid deposition. To study the pathogenesis of this disease, transgenic mice were developed with a DNA construct of a human amyloid associated apoAII gene. Animals expressing the transgene developed renal amyloid deposition by 3= to 4 months of age and subsequently amyloid in spleen, liver, and heart. Amyloid fibrils were extracted from tissues and biochemically shown to contain fulllength human apoAII with a 21 amino acid carboxyl terminal extension. The rapid development of amyloid deposition in these animals indicates that this will be a valuable model to study pathogenesis of amyloidosis plus afford a means of testing potential therapeutics.

Original languageEnglish
Pages (from-to)32-33
Number of pages2
JournalAmyloid
Volume18
Issue numberSUPPL. 1
DOIs
StatePublished - Jun 2011

Fingerprint

Amyloidosis
Amyloid
Transgenic Mice
Apolipoprotein A-II
Kidney
Terminator Codon
Apolipoproteins
Transgenes
Genes
Spleen
Amino Acids
Mutation
Liver
DNA

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Benson, M., Kalopissis, A. D., Charbert, M., Liepnieks, J. J., & Kluve-Beckerman, B. (2011). A transgenic mouse model of human systemic Apoa2 amyloidosis. Amyloid, 18(SUPPL. 1), 32-33. https://doi.org/10.3109/13506129.2010.545961

A transgenic mouse model of human systemic Apoa2 amyloidosis. / Benson, Merrill; Kalopissis, A. D.; Charbert, M.; Liepnieks, J. J.; Kluve-Beckerman, B.

In: Amyloid, Vol. 18, No. SUPPL. 1, 06.2011, p. 32-33.

Research output: Contribution to journalArticle

Benson, M, Kalopissis, AD, Charbert, M, Liepnieks, JJ & Kluve-Beckerman, B 2011, 'A transgenic mouse model of human systemic Apoa2 amyloidosis', Amyloid, vol. 18, no. SUPPL. 1, pp. 32-33. https://doi.org/10.3109/13506129.2010.545961
Benson M, Kalopissis AD, Charbert M, Liepnieks JJ, Kluve-Beckerman B. A transgenic mouse model of human systemic Apoa2 amyloidosis. Amyloid. 2011 Jun;18(SUPPL. 1):32-33. https://doi.org/10.3109/13506129.2010.545961
Benson, Merrill ; Kalopissis, A. D. ; Charbert, M. ; Liepnieks, J. J. ; Kluve-Beckerman, B. / A transgenic mouse model of human systemic Apoa2 amyloidosis. In: Amyloid. 2011 ; Vol. 18, No. SUPPL. 1. pp. 32-33.
@article{bf6a34d878fc4478a3fe8bea5e2bead5,
title = "A transgenic mouse model of human systemic Apoa2 amyloidosis",
abstract = "Apolipoprotein AII (apoAII) amyloidosis an autosomal dominant inherited form of amyloidosis caused by mutations in the stop codon for the apoAII gene is characterized by progressive renal and cardiac amyloid deposition. To study the pathogenesis of this disease, transgenic mice were developed with a DNA construct of a human amyloid associated apoAII gene. Animals expressing the transgene developed renal amyloid deposition by 3= to 4 months of age and subsequently amyloid in spleen, liver, and heart. Amyloid fibrils were extracted from tissues and biochemically shown to contain fulllength human apoAII with a 21 amino acid carboxyl terminal extension. The rapid development of amyloid deposition in these animals indicates that this will be a valuable model to study pathogenesis of amyloidosis plus afford a means of testing potential therapeutics.",
author = "Merrill Benson and Kalopissis, {A. D.} and M. Charbert and Liepnieks, {J. J.} and B. Kluve-Beckerman",
year = "2011",
month = "6",
doi = "10.3109/13506129.2010.545961",
language = "English",
volume = "18",
pages = "32--33",
journal = "Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis",
issn = "1350-6129",
publisher = "Informa Healthcare",
number = "SUPPL. 1",

}

TY - JOUR

T1 - A transgenic mouse model of human systemic Apoa2 amyloidosis

AU - Benson, Merrill

AU - Kalopissis, A. D.

AU - Charbert, M.

AU - Liepnieks, J. J.

AU - Kluve-Beckerman, B.

PY - 2011/6

Y1 - 2011/6

N2 - Apolipoprotein AII (apoAII) amyloidosis an autosomal dominant inherited form of amyloidosis caused by mutations in the stop codon for the apoAII gene is characterized by progressive renal and cardiac amyloid deposition. To study the pathogenesis of this disease, transgenic mice were developed with a DNA construct of a human amyloid associated apoAII gene. Animals expressing the transgene developed renal amyloid deposition by 3= to 4 months of age and subsequently amyloid in spleen, liver, and heart. Amyloid fibrils were extracted from tissues and biochemically shown to contain fulllength human apoAII with a 21 amino acid carboxyl terminal extension. The rapid development of amyloid deposition in these animals indicates that this will be a valuable model to study pathogenesis of amyloidosis plus afford a means of testing potential therapeutics.

AB - Apolipoprotein AII (apoAII) amyloidosis an autosomal dominant inherited form of amyloidosis caused by mutations in the stop codon for the apoAII gene is characterized by progressive renal and cardiac amyloid deposition. To study the pathogenesis of this disease, transgenic mice were developed with a DNA construct of a human amyloid associated apoAII gene. Animals expressing the transgene developed renal amyloid deposition by 3= to 4 months of age and subsequently amyloid in spleen, liver, and heart. Amyloid fibrils were extracted from tissues and biochemically shown to contain fulllength human apoAII with a 21 amino acid carboxyl terminal extension. The rapid development of amyloid deposition in these animals indicates that this will be a valuable model to study pathogenesis of amyloidosis plus afford a means of testing potential therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=79959954600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959954600&partnerID=8YFLogxK

U2 - 10.3109/13506129.2010.545961

DO - 10.3109/13506129.2010.545961

M3 - Article

AN - SCOPUS:79959954600

VL - 18

SP - 32

EP - 33

JO - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

JF - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

SN - 1350-6129

IS - SUPPL. 1

ER -